Sodium and potassium balance are maintained by matching renal excretion to dietary intake through integrated hormonal control. Aldosterone, produced by the adrenal zona glomerulosa, increases sodium reabsorption and potassium secretion in collecting duct principal cells by increasing Na-K-ATPase activity and ENaC apical sodium channel expression. The renin-angiotensin-aldosterone system (RAAS) is activated by renal hypoperfusion (decreased GFR) or hypokalemia, increasing renin secretion, angiotensin II formation, and aldosterone release to conserve sodium and expand blood volume. Atrial natriuretic peptide (ANP), released from atrial myocytes during volume expansion, inhibits renin and aldosterone secretion and directly increases sodium excretion, opposing RAAS effects.
Measure plasma electrolytes, renin, angiotensin II, and aldosterone in response to sodium restriction, diuretics, or saline infusion. Study primary hyperaldosteronism (Conn syndrome) and Addison's disease (aldosterone deficiency) as disturbances of electrolyte balance.
Aldosterone affects both sodium and potassium in opposite directions; hyperkalemia is as much a risk in aldosterone deficiency as hypokalemia is in excess aldosterone.
From your understanding of collecting duct function and ADH-mediated water reabsorption, you know that the kidney's distal segments fine-tune the composition of urine. Electrolyte balance extends this concept: the kidney does not merely adjust water — it independently regulates sodium and potassium to maintain their plasma concentrations within narrow ranges essential for cell function, nerve conduction, and cardiac rhythm. The key insight is that this regulation is not passive filtration but an actively controlled hormonal system that adjusts renal handling based on the body's current needs.
The central hormone is aldosterone, a mineralocorticoid produced by the adrenal cortex. Aldosterone acts on principal cells of the collecting duct, where it increases the expression of ENaC (epithelial sodium channels) on the apical membrane and Na⁺/K⁺-ATPase pumps on the basolateral membrane. The result is increased sodium reabsorption from the tubular fluid back into the blood, coupled with potassium secretion into the tubular fluid for excretion. This linkage is crucial: aldosterone does not just "save sodium" — it trades sodium retention for potassium loss. This is why diseases of aldosterone excess (like Conn syndrome) produce both hypertension (from sodium and water retention) and hypokalemia (from excessive potassium excretion), while aldosterone deficiency (as in Addison's disease) causes the opposite — sodium wasting, hypotension, and dangerous hyperkalemia.
Aldosterone secretion is controlled primarily by the renin-angiotensin-aldosterone system (RAAS). When the kidneys detect reduced perfusion pressure — from dehydration, hemorrhage, or low blood pressure — juxtaglomerular cells release renin, which cleaves angiotensinogen to angiotensin I. Angiotensin-converting enzyme (ACE) in the lungs converts this to angiotensin II, a potent vasoconstrictor that also stimulates aldosterone release from the adrenal glands. The net effect is sodium retention, water follows osmotically, blood volume expands, and blood pressure rises. Plasma potassium concentration also directly stimulates aldosterone secretion independent of RAAS — even a small rise in extracellular K⁺ triggers aldosterone release to increase renal potassium excretion, protecting the heart from hyperkalemia-induced arrhythmias.
Opposing the RAAS is atrial natriuretic peptide (ANP), released by atrial cardiomyocytes when they are stretched by volume expansion. ANP inhibits renin secretion, blocks aldosterone release, and directly increases sodium excretion by the kidney (natriuresis). It also promotes vasodilation, reducing blood pressure. The RAAS-ANP axis functions as a push-pull system: RAAS conserves sodium and expands volume when the body is depleted, while ANP sheds sodium and contracts volume when the body is overloaded. Clinical interventions exploit this axis — ACE inhibitors and angiotensin receptor blockers reduce aldosterone-driven sodium retention in heart failure and hypertension, while potassium-sparing diuretics block ENaC or aldosterone receptors to prevent the hypokalemia caused by other diuretics.